News ABIONYX Pharma Börse Stuttgart

Equities

609 FR0012616852

Delayed Börse Stuttgart Other stock markets 02:13:42 2024-06-17 EDT			5-day change	1st Jan Change
1.266 ^EUR	-2.62%		+13.44%	-29.74%

06-14	Abionyx: positive response from FDA, share price rises	CF
06-13	ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Abionyx: positive response from FDA, share price rises	06-14	CF
ABIONYX Pharma : has completed a successful pre IND meeting with the FDAfor CER 001 Phase 2b/3 Clinical Trial for Patients with Sepsis	06-13	PU
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis	06-13	BU
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis	06-13	BU
ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis	06-13	CI
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2024	05-16	BU
ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023	05-02	BU
Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	03-14	CF
ABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant	03-14	BU
Abionyx: reduced net loss in 2023	03-11	CF
ABIONYX Pharma Announces Its 2023 Full-Year Financial Results	03-11	BU
ABIONYX Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
ABIONYX Pharma announces its financial calendar for the year 2024	03-07	BU
Abionyx: CSL Behring fails in heart disease trial	02-16	CF
ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring?S Human-Plasma-Derived Apoa-I, CSL112	02-15	CI
Abionyx: former AbbVie executive appointed CMO	01-09	CF
ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D	01-08	CI
Abionyx: Successful completion of third GMP batch of CER-001	12-19	CF
2,867,986 Ordinary Shares of ABIONYX Pharma SA are subject to a Lock-Up Agreement Ending on 7-DEC-2023.	12-06	CI
Abionyx: encouraging results in brain fog	11-24	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ABIONYX Pharma Börse Stuttgart

Equities

609

FR0012616852

Summary

Filters